Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer
Back at the beginning of this year, Amgen stepped up with a billion-dollar smorgasbord of milestones to enlist Immatics in a campaign to create …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
